Skip to main content

Table 2 The clinical characteristics of AML patients from TCGA. CR, complete remission; MLL, mixed lineage leukemia

From: Development and validation of GMI signature based random survival forest prognosis model to predict clinical outcome in acute myeloid leukemia

  TCGAPO (N = 74) TCGAPT (N = 73)
Age at Diagnosis (year)
 median (range) 10.58 (0.40–22.55) 9.04 (0.38–19.12)
Gender
 female (n%) 34 (45.95%) 40 (54.79%)
Race
 white (n%) 59 (79.73%) 55 (75.34%)
First event
 relapse (n%) 51 (68.92%) 54 (73.97%)
CR status
 CR (n%) 69 (93.24%) 61 (83.56%)
Primary Cytogenetic
 MLL (n%) 10 (13.51%) 18 (24.66%)
 Normal (n%) 18 (24.32%) 11 (15.07%)
 Other (n%) 14 (18.92%) 20 (27.40%)
 t(8;21) 7 (9.46%) 11 (15.07%)
 inv.(16) 16 (21.62%) 12 (16.44%)
Cytogenetic Site of Relapse/Induction Failure
 Yes (n%) 4 (5.41%) 13 (17.81%)
 No (n%) 48 (64.86%) 43 (58.90%)
 Not done (n%) 22 (29.73%) 17 (23.29%)
FAB Category
 M0,M1,M2,M3,M4,M5,M6,M7,NOS 2 (2.70%),7 (9.46%),19 (25.68%),0 (0.00%),22 (29.73%),15 (20.27%),1 (1.35%),2 (2.70%),5 (6.76%) 2 (2.74%),8 (10.96%),15 (20.55%),0 (0.00%),20 (27.40%),12 (16.44%),1 (1.37%),5 (6.85%),3 (4.11%)
FLT3/ITD
 Positive (n%) 8 (10.81%) 5 (6.85%)
 Negative (n%) 66 (89.19%) 68 (93.15%)
WBC at Diagnosis
 median (range) 53.5 (2.1–302) 34.9 (1.3–519)
NPM mutation
 Yes (n%) 4 (5.41%) 2 (2.74%)
 No (n%) 66 (89.19%) 70 (95.89%)
CEBPA mutation
 Yes (n%) 4 (5.41%) 5 (6.85%)
 No (n%) 69 (93.24%) 67 (91.78%)
WT1 mutation
 Yes (n%) 4 (5.41%) 6 (8.22%)
 No (n%) 67 (90.54%) 66 (90.41%)
Protocol
 CCG-2961(n%), AAML03P1(n%), AAML0531(n%) 18 (24.3%),38 (51.4%),18 (24.3%) 0 (0%),0 (0%),73 (100%)